Michigan-based CureLauncher, developer of a patent-pending, proprietary clinical trial matching service, has entered an exclusive partnership with the National Stroke Association—an educational, prevention and advocacy group for individuals, their families and healthcare professionals confronting health issues related to strokes.

National Stroke Association members and visitors will be directed to CureLauncher’s web site (http://www.curelauncher.com), where specially trained relationship managers help individuals find a clinical trial that may offer access to a new diagnostic test, treatment or rehabilitative approach.

“We are thrilled to partner with CureLauncher,” said Jim Baranski, the asociation’s CEO. “Together, we can make progress in preventing, treating and understanding this challenging condition that impacts so many American families. In particular, clinical medical research is bringing us new diagnostic techniques to identify individuals at risk for stroke, as well as life strategies and other approaches to prevention.”

"CureLauncher redefines the approach to clinical trials by putting people and their families first," said David Fuehrer, CureLauncher’s president, who also is a two-time cancer survivor and an active speaker and volunteer for various support communities.

“We are excited to collaborate with the National Stroke Association. We want to help them in their quest to prevent or alleviate what is now the nation’s fourth leading cause of death,” Fuehrer added.

The National Stroke Association launched in 1984 to fill a void as the only national nonprofit healthcare organization focusing 100% of its resources and attention on stroke. In its brief history, the association has become a leading national resource on stroke and the driving force behind efforts to improve stroke prevention, treatment, rehabilitation and support.

CureLauncher’s matching system helps people find treatment options aligned with their unique goals and conditions.